Drug intelligence / Profile preview

REGN2009

Development stage: Phase 1
Lead developer: Regeneron Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

REGN2009 is a biological investigational drug developed by Regeneron Pharmaceuticals. It was evaluated in a phase 1, randomized, double-blind, placebo-controlled first-in-human study to assess the safety and tolerability of ascending single doses in healthy volunteers. The specific mechanism of action and target for REGN2009 have not been publicly disclosed. Development of the drug has been discontinued[2][1][3].

Beyond the preview

Go deeper on REGN2009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN2009.

Explore the full profile